Multigene panel testing for hereditary breast and ovarian cancers: An analysis of 1303 BRCA-negative Chinese patients. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...
Prescribing preferences for hormone sensitive (HR+) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback